C-RAD AB: Letter of intent to enable worldwide marketing and sales of the GEMini™ ED

Press release 2012-11-23

Letter of Intent signed to enable worldwide marketing and sales of the GEMini™ ED detector panel

C-RAD AB with its three fully owned subsidiaries in Sweden and three international sales companies are all active in the field of radiation therapy. The company has signed a Letter of Intent with Cablon Medical B.V, the Netherlands, for initiating worldwide marketing and sales of its GEMini™ ED detector together with Cablon’s clinical software for portal dosimetry and imaging.

The GEMini™ ED is an advanced flat panel detector based on the Gas Electron Multiplier (GEM) technology licensed from CERN, Switzerland. Its many unique features such as dose linearity, dose rate independence and greatly improved radiation hardness makes it the only detector on the market that is fully optimized both for portal imaging and portal dosimetry applications.

At signing of a final agreement and completion of the technical integration, a state-of-the-art solution for pre-treatment imaging, online verification and assessment of the delivered dose at each fraction will be offered to clinicians worldwide.

Erik Hedlund, CEO, C-RAD AB:

”We have for some time been looking for the right partner to bring the GEMini™ ED detector to the market. Together with Cablon’s well-proven clinical software, it is now within our reach to provide the very best package available for portal dosimetry and imaging.”

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail erik.hedlund@c-rad.se